Summary
Two thousand three hundred and thirty five plasma concentrations of tianeptine from 112 patients enrolled in nine studies of tianeptine pharmacokinetics performed prior to the marketing of the drug were pooled for analysis using mixed-effect modeling. Studies represented a combination of single dose and multiple dosing at steady-state. Tianeptine plasma concentration time data were fit to a two compartment model with first order absorption using the NONMEM computer program.
The results of this analysis suggested that alcoholism is associated with significant increase in clearance (124% increase) and volume of the central compartment (161% increase). The volume of the peripheral compartment is significantly lower in women (31% decrease) and in depressed patients (59% decrease).
The population mean (interindividual variability) clearance was equal to 0.17 l·h−1·kg−1 (28.6%), the volume of central compartment was 0.13 l·kg−1 (60.4%), intercompartmental clearance was 0.07 l·h−1·kg−1 (30.1%), volume of the tissue compartment was 1.17 l·kg−1 (28.3%), and the absorption rate constant was 0.63 h−1 (21.8%). The residual variability was approximately 30% at concentrations expected during clinical use of the drug.
Because of the increased clearance, alcoholic patients would be expected to have significantly reduced concentrations during steady-state dosing. These population parameters provide a basis for developing initial dosing recommendations and for performing bayesian evaluations of drug concentrations obtained in post-marketing studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Defrance R, Marey C, Kamoun A (1988) Antidepressant and anxiolytic activities of tianeptine. An overview of clinical trials. Clin Neuropharmacol 11: S74-S82
Loo H, Malka R, Defrance R, Barrucand D, Benard JY, Niox-Riviere H et al. (1988) Tianeptine and amitriptyline: controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology 19: 79–85
Mennini T, Mocaer E, Garattini S (1987) Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn Schmiedeberg's Arch Pharmacol 336: 478–482
Chamba G, Lemoine P, Flachaire E, Ferry N, Quincy C, Sassard J et al. (1991) Increased serotonin platelet uptake after tianeptine administration in depressed patients. Biol Psychiatry 30: 609–617
Malka R, Loo H, Ganry H, Marey C, Kamoun A (1990) Long term efficacy and clinical safety of Tianeptine in depressed alcoholic patients after alcohol withdrawal. Drug Invest 2: 224–234
Loo H, Ganry H, Dufour H, Guelfi JD, Malka R, Olie JP et al. (1992) Long term use of tianeptine in 380 depressed patients. Br J Psychiat 160: 61–65
Loo H, Ganry H, Marey C, Briole G, Castelnau D, Charbonnier JF, Dachary JM et al. (1992) Results of tianeptine psychotrope monotherapy in depressed patients treated for one year. Eur J Psychiatr 6: 29–39
Sheiner LB, Beal SL (1982) Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-bayesian methods. J Pharm Sci 71: 1344–1348
Beal SL, Sheiner LB (1980) The NONMEM System. Am Stat 34: 118
Royer RJ, Royer-Morrot MJ, Paille F, Barrucand D, Schmitt J, Defrance R, Salvadori C (1989) Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis. Clin Pharmacokinet 16: 186–191
Demotes-Mainard F, Galley P, Manciet G, Vincon G, Salvadori C (1991) Pharmacokinetics of the antidepressant tianeptine at steady-state in the elderly. J Clin Pharmacol 31: 174–178
Salvadori C, Ward C, Defrance R, Hopkins R (1990) The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans. Influence of alcohol coadministration. Fundam Clin Pharmacol 4: 115–125
Deleted
Deleted
Toon S, Holt BL, Langley SJ, Mullins FGP, Rowland M, Halliday MS, Salvadori C, Delalleau B (1990) Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state. Psychopharmacology 101: 226–232
Dresse A, Rosen JM, Brems H, Masset H, Defrance R, Salvadori C (1988) Influence of food on tianeptine and its main metabolite kinetics. J Clin Pharmacol 28: 1115–1119
Carlhant D, Le Carrec J, Guedes Y, Salvadori C, Mottier D, Riche C (1990) Pharmacokinetics and bioavailability of tianeptine in the elderly. Drug Invest 2: 167–172
Salvadori C, Merjdan H, Brouard R, Baumelou A, Nicot G, Fries D (1990) Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis. Fundam Clin Pharmacol 4: 663–671
Nicot G, Lachatre G, Gonnet C, Mallon J, Mocaer E (1986) Paired ion extraction and high performance liquid chromatographic determination of tianeptine and its metabolites in human plasma urine and tissues. J Chromatogr Biomed Appl 381: 115–126
Beal SL, Sheiner LB (ed) (1992) Lecture notes. A short course in population pharmacokinetic data analysis using the NONMEM system. San Francisco, CA
Sanathanan LP, Peck CC (1991) The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Controlled Clin Trials 12: 780–794
Maitre PO, Buhrer M, Thomson D, Stanski DR (1991) A three-step approach combining bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokin Biopharm 19: 377–384
Sheiner LB, Beal SL (1983) Pharmacometrics: evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokin Biopharmaceut 11: 303–319
Grasela TH, Antal EJ, Townsend RJ, Smith RB (1986) An evaluation of population pharmacokinetics in therapeutic trials. Comparison of methodologies. Clin Pharmacol Therap 39: 605–612
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grasela, T.H., Fiedler-Kelly, J.B., Salvadori, C. et al. Development of a population pharmacokinetic database for tianeptine. Eur J Clin Pharmacol 45, 173–179 (1993). https://doi.org/10.1007/BF00315502
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315502